DNMT3A had a missense mutation predicted to be damaging to protein function in the initial clone of a triple-proficient and chemonaive cancer (DNMT3AR488Q, PolyPhen-2 score, 0.48; Supplemental Figure 16A) as well as a frameshift deletion of 37 base pairs in a disseminated clone of a cancer with HRD exposed to neoadjuvant chemotherapy (Supplemental Figure 20). This evidence concerns the gene DNMT3A and cancer.